Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 80 for “"KRAS mutation"”.

  1. Kras mutation in eutopic endometrium and development of endometriosis : a novel mouse model

    … subtype of endometriosis, tend to have a mutation in KRAS codon 12 confined to the epithelium of the endometriosis lesions and within the eutopic endometrium [5]. To achieve a deeper understanding of the roles of the KRAS mutation in the development of endometriosis, this thesis has two …

    ubc Repository record for Kras mutation in eutopic endometrium and development of endometriosis : a novel mouse model (opens in a new tab) Download PDF for Kras mutation in eutopic endometrium and development of endometriosis : a novel mouse model (opens in a new tab)

  2. p53 loss and Kras mutation in an invasive murine model of colorectal cancer

    … recapitulate the human disease by manipulating mutations that occur during colorectal cancer (CRC) progression. The p53 tumour suppressor gene is commonly mutated in sporadic CRC, though loss alone does not drive intestinal tumorigenesis. When we targeted p53 deletion to the adult murine …

    glasgow Download PDF for p53 loss and Kras mutation in an invasive murine model of colorectal cancer (opens in a new tab)

  3. Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer

    … liquid biopsy for detecting oncogenic KRAS hotspot mutations (G12/G13), which occur in over 90% of PDAC cases. A pilot study of patients with PDAC and other gastrointestinal malignancies was enrolled through the BC Cancer Agency in Vancouver. Paired urine and plasma samples were …

    ubc Repository record for Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer (opens in a new tab) Download PDF for Trans-renal tumor DNA as a non-invasive liquid biopsy for KRAS mutation detection in pancreatic cancer (opens in a new tab)

  4. INVESTIGATION OF RAS-DEPENDENT GENE EXPRESSION & CELL SURVIVAL SIGNALLING IN COLORECTAL CANCER

    KRAS MUTATION OCCURS IN UP TO 60% OF COLORECTAL CANCERS (CRC) AND DEVELOPMENT OF EFFECTIVE TARGETED THERAPIES STILL REMAINS A CHALLENGE. STUDIES HAVE HIGHLIGHTED THE ISSUE OF KRAS DEPENDENCY AND INDEPENDENCY, IMPLYING THAT KRAS MUTATION STATUS IS INADEQUATE AS A BIOMARKER OF TREATMENT RESPONSE. …

    nus Repository record for INVESTIGATION OF RAS-DEPENDENT GENE EXPRESSION & CELL SURVIVAL SIGNALLING IN COLORECTAL CANCER (opens in a new tab) Download file for INVESTIGATION OF RAS-DEPENDENT GENE EXPRESSION & CELL SURVIVAL SIGNALLING IN COLORECTAL CANCER (opens in a new tab)

  5. c-MET and KRAS: Signalling and Clinical Implications in Colorectal Cancer

    … cause of death from cancer in North America. The KRAS gene is mutated in approximately 40-50% of all CRC, and this mutation precludes treatment with promising targeted therapeutics. c-MET is a receptor tyrosine kinase that is overexpressed in ~70% of CRCs, and expression is correlated with disease …

    toronto-retro Repository record for c-MET and KRAS: Signalling and Clinical Implications in Colorectal Cancer (opens in a new tab)

  6. Targeting PI3-kinase signalling in genetically engineered mouse models of intestinal cancer

    … tumour suppressor Apc. Moreover, PI3-Kinase and Kras mutations, which co-occur in human CRC, strongly synergise to drive intestinal tumour initiation and alter the transcriptional landscape. Using these advanced preclinical models as a platform, I have now interrogated the therapeutic impact of …

    glasgow Repository record for Targeting PI3-kinase signalling in genetically engineered mouse models of intestinal cancer (opens in a new tab) Download PDF for Targeting PI3-kinase signalling in genetically engineered mouse models of intestinal cancer (opens in a new tab)

  7. The Impact of Microenvironmental Mediators on the Malignant Progression of Colorectal Cancer

    … malignantly, especially in patients with a mutation in the Kirsten rat sarcoma virus (KRAS) gene. Mechanics is an important driver of malignant progression in many cancers, but the understanding of CRC progression in the context of colonic peristalsis (native mechanics of the colon) is …

    tamu Repository record for The Impact of Microenvironmental Mediators on the Malignant Progression of Colorectal Cancer (opens in a new tab)

  8. The influence of the EGFR pathway in modulating the efficacy of gemcitabine

    … be caused by antagonism between the two drugs or mutations that promote such, possibly RAS mutation. Furthermore, ERK, a critical growth regulator downstream of RAS, may play a role. Therefore the aim of this study is to explore the cytotoxic interaction between gemcitabine and an EGFR inhibitor …

    unsw Repository record for The influence of the EGFR pathway in modulating the efficacy of gemcitabine (opens in a new tab)

  9. Effects of Low-Dose Gamma Radiation in a Murine Model of Benzo[a]pyrene-Induced Lung Cancer

    … to investigate the effects of LDR and B[a]P on Kras mutation in tumors, leukocyte cytotoxicity and function, and oxidative stress in mice. Treatment with fractionated doses of LDR (100 mGy) delivered post B[a]P injection suppressed carcinogen-induced lung adenoma formation and prevented the …

    unm Repository record for Effects of Low-Dose Gamma Radiation in a Murine Model of Benzo[a]pyrene-Induced Lung Cancer (opens in a new tab)

  10. Signaling crosstalk in cancers

    … spectrum of genetic alterations, among which KRAS mutation is the most prominent component with a detection frequency as high as 90%. Hedgehog signaling pathway is involved in developmental process and it’s reactivated in the early stage of carcinogenesis of pancreatic cancer. The coincidence …

    utmb Repository record for Signaling crosstalk in cancers (opens in a new tab)

  11. The emerging role of genetic data in the surgical treatment of patients with colorectal cancer liver metastasis

    … in this thesis is largely focused on the role of KRAS and BRAF mutation status in determining prognosis and guiding management among patients with resectable CRLM. The decision to focus our investigation on these two biomarkers reflects both their central importance in colorectal carcinogenesis …

    fu-berlin Repository record for The emerging role of genetic data in the surgical treatment of patients with colorectal cancer liver metastasis (opens in a new tab)

  12. Role of ER-phagy and proteostatic defects in pancreatic cancer

    … in pancreatic ductal adenocarcinoma (PDAC), Kras mutation in pancreatic acinar cells in mouse models does not lead to immediate morphological changes. Indeed, the molecular events driven by Kras that precede and facilitate the earliest transformation towards malignancy, such as acinar-ductal …

    edinburgh Repository record for Role of ER-phagy and proteostatic defects in pancreatic cancer (opens in a new tab)

  13. The Kras/Mapk Pathway and Ligand Independent Activation of Erα: Implications For The Treatment of Endometrial Cancer

    … demonstrated that tumors with an activating KRas mutation are resistant to treatment with letrozole even in combination with everolimus. Tumor growth and cellular proliferation were reduced only after the addition of metformin. To assess signaling through ERα, cells with and without an …

    uthsc Repository record for The Kras/Mapk Pathway and Ligand Independent Activation of Erα: Implications For The Treatment of Endometrial Cancer (opens in a new tab)

  14. Προσδιορισμός των μεταλλάξεων του BRAF γονιδίου στον καρκίνο του παχέος εντέρου

    … the predictive and prognosticinfluence of BRAF mutation and other molecular, clinicaland laboratory parameters in stage IV colorectal cancer(CRC). 60 patients were included in this retrospective analysis,and 17 variables were examined for their relation withtreatment response and survival. KRAS …

    greece Repository record for Προσδιορισμός των μεταλλάξεων του BRAF γονιδίου στον καρκίνο του παχέος εντέρου (opens in a new tab)

  15. Prognostic role of tumour associated trypsin inhibitor in colorectal cancer patients

    … proteins pSTAT3 and pERK1/2, as well as KRAS mutation status. Apart from a significant association between t-TATI expression and KRAS mutation status, there was no intercorrelation between t-TATI or s-TATI and the investigative markers. Expression of pERK1/2 and pSTAT3, and KRAS mutation …

    lund Repository record for Prognostic role of tumour associated trypsin inhibitor in colorectal cancer patients (opens in a new tab) Download PDF for Prognostic role of tumour associated trypsin inhibitor in colorectal cancer patients (opens in a new tab)

  16. Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test

    <p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is …

    dominican Repository record for Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test (opens in a new tab)

  17. An in vivo inflammatory loop potentiates KRAS blockade

    KRAS inhibitors perform inferior to other targeted drugs. To investigate a possible reason for this, we treated cancer cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isoprenylcysteine carboxylmethyltransferase), and AA12 (targeting KRASG12C), and …

    lmu-germany Repository record for An in vivo inflammatory loop potentiates KRAS blockade (opens in a new tab)

  18. Targeting Ras Neoantigens with Novel Cancer Immunotherapies

    … for targeting tumor-specific antigens exist. Mutation-associated neoantigens (MANAs) are peptides derived from intracellular mutant proteins that are presented on the cell surface in peptide-HLA complexes. Targeting MANAs offers a strategy to eliminate cancer cells harboring driver mutations …

    jhu Repository record for Targeting Ras Neoantigens with Novel Cancer Immunotherapies (opens in a new tab) Embargoed until 2027-05-01

Page 1 of 4